Enhancing phage therapy through synthetic biology and genome engineering
Bryan R Lenneman, Jonas Fernbach, Martin J Loessner, Timothy K Lu, Samuel Kilcher, Bryan R Lenneman, Jonas Fernbach, Martin J Loessner, Timothy K Lu, Samuel Kilcher
Abstract
The antimicrobial and therapeutic efficacy of bacteriophages is currently limited, mostly due to rapid emergence of phage-resistance and the inability of most phage isolates to bind and infect a broad range of clinical strains. Here, we discuss how phage therapy can be improved through recent advances in genetic engineering. First, we outline how receptor-binding proteins and their relevant structural domains are engineered to redirect phage specificity and to avoid resistance. Next, we summarize how phages are reprogrammed as prokaryotic gene therapy vectors that deliver antimicrobial 'payload' proteins, such as sequence-specific nucleases, to target defined cells within complex microbiomes. Finally, we delineate big data- and novel artificial intelligence-driven approaches that may guide the design of improved synthetic phage in the future.
Trial registration: ClinicalTrials.gov NCT03808103 NCT04191148.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Source: PubMed